OSTEOGENESIS IMPERFECTA, TYPE XVII
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Recessive osteogenesis imperfecta caused by missense mutations in SPARC.
|
26027498 |
2015 |
OSTEOGENESIS IMPERFECTA, TYPE XVII
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recessive osteogenesis imperfecta caused by missense mutations in SPARC.
|
26027498 |
2015 |
OSTEOGENESIS IMPERFECTA, TYPE XVII
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recessive osteogenesis imperfecta caused by missense mutations in SPARC.
|
26027498 |
2015 |
OSTEOGENESIS IMPERFECTA, TYPE XVII
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
OSTEOGENESIS IMPERFECTA, TYPE XVII
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Osteogenesis Imperfecta
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Recently, mutations in the gene encoding SPARC were found in patients afflicted with osteogenesis imperfecta.
|
29310786 |
2018 |
Osteogenesis Imperfecta
|
0.520 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Recessive osteogenesis imperfecta caused by missense mutations in SPARC.
|
26027498 |
2015 |
Osteogenesis Imperfecta
|
0.520 |
AlteredExpression
|
disease |
BEFREE |
Not only have specific bone cell matrix components (collagen, osteonectin, the large chondroitin sulfate proteoglycan, biglycan, and decorin) been found to be present in reduced levels in OI bone cells, but some matrix components (thrombospondin, fibronectin, and hyaluronan) have also been found to be present in elevated levels in the matrix of OI cells.(ABSTRACT TRUNCATED AT 250 WORDS)
|
7484289 |
1995 |
Osteogenesis Imperfecta
|
0.520 |
Biomarker
|
disease |
CTD_human |
Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility.
|
1793673 |
1991 |
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.
|
18615449 |
2008 |
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
RGD |
Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.
|
18615449 |
2008 |
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.
|
18615449 |
2008 |
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
RGD |
Osteonectin gene expression in fibrotic liver.
|
8786698 |
1996 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry analysis revealed two patterns: Positive staining of SPON2 and SPP1 in epithelial cells of healthy mucosa and dysplastic glands of CRA and CRC, and positive staining of DCN and SPARC in the lamina propria in healthy mucosa and stroma of CRA and CRC.
|
31524274 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, this observation correlates with tissue microarray analysis of 143 human CRC, where low GRP78 to SPARC expression level was prognostic of higher survival rate (P = 0.01) in individuals with CRC.
|
31243264 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As for stromal expression, SPARC indicates a poorer prognosis in pancreatic cancer, but a better disease-free survival in colorectal cancer.
|
31423511 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, stromal SPARC had a pro-metastatic impact in vitro and was a characteristic of aggressive tumors with poor prognosis in CRC patients.
|
31554208 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data showed that has-mir-29c-3p regulates CRC cell functions through regulating SPARC expression.
|
29262657 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the relationship between the expression of SPARC, ITGAV, THBS1 and VCAM-1 genes of extracellular matrix in the progression and dissemination of colorectal cancer (CRC).
|
25275062 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results suggested that the epigenetic regulation of SPARC expression in tumor cells versus stromal cells of CRC is significantly different.
|
21725199 |
2011 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor.
|
18849185 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also demonstrate that SPARC repression in CRC cell lines could be reversed following exposure to 5-Aza, which resulted in increased SPARC expression, leading to a significant reduction in cell viability (by an additional 39% in RKO cells) and greater apoptosis (an additional 18% in RKO cells), when combined with 5-FU in vitro (in comparison to 5-FU alone).
|
18458674 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We also demonstrate that SPARC repression in CRC cell lines could be reversed following exposure to 5-Aza, which resulted in increased SPARC expression, leading to a significant reduction in cell viability (by an additional 39% in RKO cells) and greater apoptosis (an additional 18% in RKO cells), when combined with 5-FU in vitro (in comparison to 5-FU alone).
|
18458674 |
2008 |